Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of Fenticonazole Nitrate Vaginal Capsules for treatment of Vulvovaginal Candidiasis (VVC) under the brand name Fenticad™.

In a commitment to further strengthening the women’s healthcare portfolio Cadila’s Fenticad™ will be 35% more cost effective and a drug of choice. Fenticad™ will be made available in 600 mg tablets.

VVC affects up to 75% of women once in their lifetime and severely impacts their quality of life. Almost 37% of women in rural India suffers from VVC in their reproductive age.* Itching (pruritus) and increased vaginal discharge are the most typical symptoms. Other symptoms are variable: soreness and burning, painful sexual intercourse (dyspareunia), or discomfort passing urine (dysuria). These symptoms may also occur in other vaginal infections.

A recent dipstick survey revealed that 36% of women went into social isolation when they were having VVC and 33% women admitted that symptoms of VVC impacted their self-confidence (Data on file).

Diabetes, pregnancy, inadequate intimate hygiene, unprotected and intense sexual activity, and antibiotic treatment can lead to high risk of developing VVC. During pregnancy, topical anti- fungal treatment (such as fenticonazole, clotrimazole, fluconazole) with the preparation of vaginal capsule or cream is preferred.